PZ0191
Crizotinib
≥98% (HPLC), c-Met (hepatocyte growth factor receptor) inhibitor, powder
동의어(들):
(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, PF 2341066, PF-02341066, PF02341066, Xalkori
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C21H22Cl2FN5O
CAS 번호:
Molecular Weight:
450.34
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
Crizotinib, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to tan
storage temp.
room temp
SMILES string
C[C@@H](Oc1cc(cnc1N)-c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl
InChI
1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
InChI key
KTEIFNKAUNYNJU-GFCCVEGCSA-N
Application
Crizotinib has been used:
- to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis
- to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells
- to restore sensitivity to erlotinib
Biochem/physiol Actions
ATP-competitive c-MET / ALK Inhibitor
Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). Crizotinib is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
signalword
Warning
hcodes
Hazard Classifications
Aquatic Acute 1 - Eye Irrit. 2 - Muta. 2 - Skin Sens. 1
저장 등급
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
문서
Discover Bioactive Small Molecules for Kinase Phosphatase Biology
관련 콘텐츠
키나아제 포스파타아제 생물학을 위한 생체 활성 저분자
Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
Greenfield E, et al.
eLife, 3, e04037-e04037 (2014)
Shota Yamamoto et al.
Radiology, 272(2), 568-576 (2014-06-03)
To present a radiogenomic computed tomographic (CT) characterization of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) (ALK+). In this HIPAA-compliant institutional review board-approved retrospective study, CT studies, ALK status, and clinical-pathologic data in 172 patients with NSCLC from
PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells
Chen C, et al.
Experimental and Therapeutic Medicine, 15(5), 4543-4549 (2018)